RNA vs LXEO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 03, 2026

RNA

53.9
AI Score
VS
RNA Wins

LXEO

39.6
AI Score

Investment Advisor Scores

RNA

54score
Recommendation
HOLD

LXEO

40score
Recommendation
SELL

AI Analyst Insights

Detailed Metrics Comparison

Metric RNA LXEO Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 1148.3% 0.0% RNA
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 53.9/100 39.6/100 RNA
Profit Margin -160.0% 0.0% LXEO
Beta 1.00 1.00 Tie
AI Recommendation HOLD SELL RNA

Relative Price Performance (Last 90 Days)

RNA 1M: -14.7% · 3M: -11.1% LXEO 1M: -7.2% · 3M: -27.5%

Current Technical Phase

RNA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 37

RSI (14): 37.0 · Price: $11.35

LXEO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -8.2%), weak momentum, RSI 37

RSI (14): 37.0 · Price: $4.13

Fundamentals Snapshot

Metric RNA LXEO
Market Cap
Forward P/E -1.9 -3.3
Trailing P/E
Revenue (TTM)
Revenue Growth 11.5% 0.0%
Gross Margin -0.3%
Operating Margin -0.9% 0.0%
EPS -5.02 -1.10
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, RNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.